Search Videos and More

Showing 109 - 120 of 439 results

Previous| 1... 9 | 10 | 11 ...37 |Next


News

Dana-Farber Research Publication 8.15.2021

Read more about the highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors. 
Ultrasensitive Blood Test Detects ‘Pan-Cancer’ Biomarker News

Ultrasensitive Blood Test Detects ‘Pan-Cancer’ Biomarker

Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.
Dana-Farber Research Publication 10.1.2023 News

Dana-Farber Research Publication 10.1.2023

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors.
Dana-Farber Research Publication 10.01.2022 News

Dana-Farber Research Publication 10.01.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction News

Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction

Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines News

New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines

In order to accurately assess the efficacy of novel therapies for brain tumors it is necessary to have reliable criteria to determine response or progression.
Study Provides New Look at why Rare Cancer Often Evades Treatments News

Study Provides New Look at why Rare Cancer Often Evades Treatments

Researchers at Dana-Farber Cancer Institute and Boston Medical Center conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single cell resolution, unlocking new insights into this rare and often hard-to-treat cancer.
Deep Learning Reveals Valuable Clues About Kidney Cancer in Pathology Slides News

Deep Learning Reveals Valuable Clues About Kidney Cancer in Pathology Slides

A team of Dana-Farber researchers has identified a potential new way to assess clinically valuable features of clear cell renal cell carcinoma (ccRCC), a form of kidney cancer, using image processing with deep learning.
Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma News

Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology.
Dana-Farber Research Publication 09.15.2023 News

Dana-Farber Research Publication 09.15.2023

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Dana-Farber Research Publication 9.15.2022 News

Dana-Farber Research Publication 9.15.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Dana-Farber Study Finds Up-front Chemotherapy Boost Could Benefit Patients with Non-Small Cell Lung Cancer News

Dana-Farber Study Finds Up-front Chemotherapy Boost Could Benefit Patients with Non-Small Cell Lung Cancer

In a phase 3 global clinical trial called FLAURA2 led by researchers from Dana-Farber Cancer Institute and Institut Gustav Roussy in France, patients with non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation taking standard therapy plus chemotherapy had a median of nearly 9 months increase in progression free survival compared with patients taking standard therapy alone.

Showing 109 - 120 of 439 results

Previous| 1... 9 | 10 | 11 ...37 |Next